LRRC4 Inhibitors
Chemical inhibitors of LRRC4 can exert their inhibitory effects through various mechanisms, primarily by targeting signaling pathways and kinases that are upstream or directly involved with the functional activity of LRRC4. PD98059 and U0126 are both inhibitors of MEK, a kinase that phosphorylates and activates ERK, which in turn is known to interact with LRRC4. By inhibiting MEK, these chemicals prevent the subsequent phosphorylation and activation of ERK, leading to a downregulation of the ERK signaling pathway that LRRC4 is part of. Consequently, the functional activity of LRRC4 is inhibited. Similarly, BIX 02189 and SL327, while also functioning as MEK inhibitors, specifically target the MEK5 and MEK1/2 isoforms, respectively, thus providing a broader inhibition of the ERK pathway connections to LRRC4.
LY294002 and Wortmannin target the PI3K/Akt pathway by inhibiting PI3K, resulting in reduced phosphorylation and activation of Akt. Since LRRC4 has been implicated in the PI3K/Akt signaling pathway, the inhibition of PI3K leads to a dampening of downstream signaling wherein LRRC4 participates, culminating in the functional inhibition of LRRC4. Rapamycin, by inhibiting mTOR, which is downstream of PI3K/Akt, further attenuates the signaling pathways involving LRRC4. Inhibition of the Src family kinases by PP2 can also lead to diminished LRRC4-related signaling, given the association of LRRC4 with Src signaling. On the other hand, SB203580 and SP600125, which inhibit p38 MAP kinase and JNK respectively, disrupt different arms of the MAP kinase signaling network, thereby decreasing the functional capabilities of LRRC4 within these contexts. Finally, Y-27632 disrupts the Rho/ROCK pathway crucial for cytoskeletal dynamics where LRRC4 may be functionally relevant, and Gefitinib, an EGFR inhibitor, by blocking EGFR, decreases the activation of downstream signaling pathways where LRRC4 is operational, thus inhibiting the functional activity of LRRC4.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
Inhibits MEK, which is upstream of the ERK pathway; LRRC4 is known to interact with ERK signaling, and inhibition of MEK by PD98059 would lead to decreased ERK activity, thus inhibiting LRRC4-associated signaling. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
A selective inhibitor of MEK1/2, leading to suppression of the MAPK/ERK pathway; since LRRC4 signaling is linked to the MAPK/ERK cascade, U0126 inhibition of this pathway would result in the functional inhibition of LRRC4. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A potent inhibitor of PI3K, which is a part of the PI3K/Akt pathway; LRRC4 has been implicated in this pathway, and inhibition of PI3K by LY294002 results in decreased Akt phosphorylation, thereby inhibiting downstream LRRC4 signaling. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Another PI3K inhibitor that would prevent the activation of Akt; since LRRC4 is associated with the PI3K/Akt pathway, inhibition of PI3K by Wortmannin leads to a reduction in the functionality of LRRC4. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
An mTOR inhibitor; mTOR is downstream of PI3K/Akt signaling, and by inhibiting mTOR, Rapamycin would attenuate the signaling pathways in which LRRC4 is involved, leading to its functional inhibition. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
Inhibits Src family kinases; LRRC4 is known to be associated with Src signaling, and by inhibiting Src kinases, PP2 would effectively reduce LRRC4-mediated signaling processes. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
Inhibits p38 MAP kinase, which is implicated in stress and inflammatory responses; by inhibiting p38, SB203580 would impair the kinase's interaction with LRRC4, leading to inhibition of LRRC4's function. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An inhibitor of c-Jun N-terminal kinase (JNK); JNK interacts with signaling pathways involving LRRC4, and inhibition by SP600125 would lead to decreased LRRC4 function. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Inhibits ROCK kinase; given that LRRC4 is involved in cytoskeletal rearrangements through Rho GTPases, which are regulated by ROCK, inhibition by Y-27632 would lead to functional inhibition of LRRC4. | ||||||
BIX 02189 | 1094614-85-3 | sc-364436 sc-364436A | 5 mg 10 mg | $224.00 $386.00 | 5 | |
A selective inhibitor of MEK5, which is part of the ERK5 pathway; as LRRC4 interacts with ERK signaling, inhibition of MEK5 by BIX 02189 would disrupt LRRC4's signaling pathway. | ||||||